The FDA recently approved the biosimilar infliximab and found that from an immunogenicity profile it was more or less similar, which is important for payers and providers, explained Jeremy Schafer, PharmD, MBA, vice president and director of specialty solutions at Precision For Value.
The FDA recently approved the biosimilar infliximab and found that from an immunogenicity profile it was more or less similar, which is important for payers and providers, explained Jeremy Schafer, PharmD, MBA, vice president and director of specialty solutions at Precision For Value.
Transcript (slightly modified)
What is the most recent data on the immunogenicity of biosimilars?
I think the most recent data that will resonate most with this audience, that they’re paying the most attention to, is going to be the biosimilar infliximab that the FDA recently approved. And, in that data they found from a immunogenicity profile that it is more or less similar, and that’s going to be a very important component for any biosimilar manufacturer because I think that a lot of payers and providers are going to assume that yeah the efficacy is probably pretty similar and safety, sure, but immunogenicity: is there going to be differences? Because maybe the manufacturing was a little bit different, or some of the inert ingredients are a little bit different, and particularly if we’re thinking of changing patients from the brand to the biosimilar then immunogenicity is really going to matter.
Reducing Time Sitting Can Help Lower BP in Older Adults, Randomized Trial Finds
April 20th 2024The randomized trial found that reducing sitting time over a 6-month period was association with reduced systolic blood pressure (BP) among a group of older patients with obesity and high rates of hypertension.
Read More
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More